摩根中国生物医药混合(QDII)A(001984)利润分配表
|
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
收入 |
-77,034,585.41 |
-77,933,714.61 |
-179,952,772.29 |
-135,295,642.64 |
利息合计 |
203,447.46 |
141,606.91 |
802,564.02 |
259,594.14 |
其中:存款利息收入 |
203,447.46 |
141,606.91 |
475,481.89 |
259,594.14 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
327,082.13 |
- |
投资收益合计 |
-109,679,838.89 |
-95,650,711.18 |
-153,095,666.32 |
-107,102,499.82 |
其中:股票投资收益 |
-113,810,856.75 |
-98,244,795.03 |
-157,044,812.58 |
-110,328,893.37 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
- |
- |
- |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
4,131,017.86 |
2,594,083.85 |
3,949,146.26 |
3,226,393.55 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
31,020,938.89 |
17,180,477.94 |
-28,507,291.54 |
-29,975,714.81 |
其他收入 |
101,339.70 |
44,134.25 |
342,572.67 |
267,709.16 |
费用 |
8,073,387.79 |
4,223,820.66 |
12,078,208.70 |
6,932,041.81 |
管理人报酬 |
6,766,031.88 |
3,526,990.46 |
10,145,636.20 |
5,829,671.68 |
基金托管费 |
1,127,671.93 |
587,831.70 |
1,690,939.41 |
971,611.95 |
销售服务费 |
5,505.28 |
2,610.08 |
280.04 |
- |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
174,178.70 |
106,388.42 |
241,353.05 |
130,758.18 |
利润总额 |
-85,107,973.20 |
-82,157,535.27 |
-192,030,980.99 |
-142,227,684.45 |